Shownotes Transcript
“Biomarkers give us information not only to diagnose a patient, but also to see whether a patient is going to have GVHD in the near future, whether a patient is going to respond to the treatment we’ll give, and what would be the overall outcome and survival.” ONS member Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP®, research nurse practitioner at MD Anderson Cancer Center in Houston, TX, talks with Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, about managing acute and chronic graft-versus-host disease (GVHD) and biomarkers for the condition. You can earn free NCPD contact hours by completing the evaluation linked in the episode notes.
Music Credit: "Fireflies and Stardust)" by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation.
Episode Notes
Check out these resources from today’s episode:
- The NCPD activity for this episode has expired, but you can still earn NCPD through many other Oncology Nursing Podcast episodes. Find a full list of opportunities). Kalariya et al.’s Oncology Nursing Forum article: Diagnostic and Prognostic Biomarkers for Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation) ONS course: Hematopoietic Stem Cell Transplantation) ONS Huddle Card™: Hematopoietic Stem Cell Transplantation)
- ONS Voice* articles about GVHD) National Institutes of Health’s GVHD Working Group reports) UpToDate results for GVHD research)
To discuss the information in this episode with other oncology nurses, visit the ONS Communities).
To provide feedback or otherwise reach ONS about the podcast, email [email protected]).